WO1998004574A1 - Preparation of crystal form ii of clarithromycin - Google Patents

Preparation of crystal form ii of clarithromycin Download PDF

Info

Publication number
WO1998004574A1
WO1998004574A1 PCT/US1997/013166 US9713166W WO9804574A1 WO 1998004574 A1 WO1998004574 A1 WO 1998004574A1 US 9713166 W US9713166 W US 9713166W WO 9804574 A1 WO9804574 A1 WO 9804574A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbon atoms
sep
methylerythromycin
solvent
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/013166
Other languages
English (en)
French (fr)
Inventor
Jih-Hua Liu
David A. Riley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27102712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1998004574(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/681,695 external-priority patent/US5844105A/en
Priority to EP97934319A priority Critical patent/EP0915899B1/en
Priority to IL12783397A priority patent/IL127833A/en
Priority to CA002261732A priority patent/CA2261732C/en
Priority to JP50903898A priority patent/JP4104660B2/ja
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to DE0000915899T priority patent/DE97934319T1/de
Priority to AT97934319T priority patent/ATE272646T1/de
Priority to AU37405/97A priority patent/AU733646B2/en
Priority to DE69730138T priority patent/DE69730138T2/de
Publication of WO1998004574A1 publication Critical patent/WO1998004574A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US1997/013166 1996-07-29 1997-07-28 Preparation of crystal form ii of clarithromycin Ceased WO1998004574A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DE69730138T DE69730138T2 (de) 1996-07-29 1997-07-28 Herstellung von kristallinen form ii von clarithromycin
AU37405/97A AU733646B2 (en) 1996-07-29 1997-07-28 Preparation of crystal form II of clarithromycin
IL12783397A IL127833A (en) 1996-07-29 1997-07-28 Preparation of the crystalline form II of clarithromycin
CA002261732A CA2261732C (en) 1996-07-29 1997-07-28 Preparation of crystal form ii of clarithromycin
JP50903898A JP4104660B2 (ja) 1996-07-29 1997-07-28 クラリスロマイシンの結晶形態ｉｉの製造
EP97934319A EP0915899B1 (en) 1996-07-29 1997-07-28 Preparation of crystal form ii of clarithromycin
DE0000915899T DE97934319T1 (de) 1996-07-29 1997-07-28 Herstellung von kristallinen form ii von clarithromycin
AT97934319T ATE272646T1 (de) 1996-07-29 1997-07-28 Herstellung von kristallinen form ii von clarithromycin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/681,695 US5844105A (en) 1996-07-29 1996-07-29 Preparation of crystal form II of clarithromycin
US90027197A 1997-07-25 1997-07-25
US08/900,271 1997-07-25
US08/681,695 1997-07-25

Publications (1)

Publication Number Publication Date
WO1998004574A1 true WO1998004574A1 (en) 1998-02-05

Family

ID=27102712

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/013166 Ceased WO1998004574A1 (en) 1996-07-29 1997-07-28 Preparation of crystal form ii of clarithromycin

Country Status (12)

Country Link
EP (1) EP0915899B1 (cg-RX-API-DMAC7.html)
JP (4) JP4104660B2 (cg-RX-API-DMAC7.html)
KR (1) KR100524214B1 (cg-RX-API-DMAC7.html)
AT (1) ATE272646T1 (cg-RX-API-DMAC7.html)
AU (1) AU733646B2 (cg-RX-API-DMAC7.html)
CA (1) CA2261732C (cg-RX-API-DMAC7.html)
DE (3) DE69730138T2 (cg-RX-API-DMAC7.html)
DK (1) DK0915899T3 (cg-RX-API-DMAC7.html)
ES (1) ES2173057T3 (cg-RX-API-DMAC7.html)
IL (1) IL127833A (cg-RX-API-DMAC7.html)
PT (1) PT915899E (cg-RX-API-DMAC7.html)
WO (1) WO1998004574A1 (cg-RX-API-DMAC7.html)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031699A1 (en) * 1997-01-17 1998-07-23 Abbott Laboratories Crystal form 0 of clarithromycin
WO2000014099A1 (en) * 1998-09-09 2000-03-16 Hanmi Pharm. Co., Ltd. Method of preparing form ii crystals of clarithromycin
WO2000035934A1 (en) * 1998-12-11 2000-06-22 Biochemie S.A. Macrolide intermediates in the preparation of clarithromycin
KR20010008496A (ko) * 1999-07-01 2001-02-05 유충식 6-오-메틸 에리트로마이신의 제조방법
EP1097938A1 (en) * 1999-10-21 2001-05-09 Hanmi Pharm. Co., Ltd. Method for preparing form II crystals of clarithromycin
WO2001068662A1 (en) * 2000-03-15 2001-09-20 Hanmi Pharm. Co., Ltd. Method of preparing clarithromycin of form ii crystals
KR100361397B1 (ko) * 2000-03-15 2002-11-23 한미약품공업 주식회사 에리스로마이신 에이 9-오-트로필옥심 유도체를 이용한클라리스로마이신의 제조방법
WO2002094843A1 (en) * 2001-05-22 2002-11-28 Pfizer Products Inc. Crystal forms of azithromycin
KR100367981B1 (ko) * 2000-11-23 2003-01-14 한미약품공업 주식회사 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물
EP1280535A4 (en) * 2000-01-11 2003-02-05 Teva Pharma PROCESSES FOR THE PREPARATION OF POLYMORPHIC FORMS OF CLARITHROMYCIN
EP1254146A4 (en) * 1999-12-16 2003-04-16 Teva Pharma PROCESSES FOR THE PREPARATION OF CLARITHROMYCIN POLYMORPHS AND A NEW POLYMORPH IV
US6617436B2 (en) 2000-02-29 2003-09-09 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
US6627743B1 (en) 1999-12-03 2003-09-30 Abbott Laboratories 6-O-methylerythromycin A crystal form III
KR100408848B1 (ko) * 2001-03-12 2003-12-06 주식회사 씨트리 클래리스로마이신의 정제방법
WO2004007518A1 (en) * 2002-07-15 2004-01-22 Korea United Pharm, Inc. Erythromycin a 9-o-pseudosaccharinyloxime derivatives and process for the preparation of clarithromycin using the same
EP1435359A1 (en) * 2002-12-31 2004-07-07 Alembic Limited A process for the purification of roxithromycin
US6861413B2 (en) 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
USRE39087E1 (en) 1998-08-21 2006-05-02 Apotex, Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
EP1652851A1 (en) * 2001-05-22 2006-05-03 Pfizer Products Inc. New crystal form of Azithromycin
DE102007016367A1 (de) 2007-04-03 2008-10-09 Grünenthal GmbH Polymorph von Clarithromycin (Form V)
CN103087130A (zh) * 2013-02-06 2013-05-08 浙江国邦药业有限公司 一种克拉霉素晶型转换方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384921B2 (en) * 2004-02-20 2008-06-10 Enanta Pharmaceuticals, Inc. Polymorphic forms of 6-11 bicyclic ketolide derivatives
MX2009005977A (es) * 2006-12-05 2009-06-17 Pfizer Polimorfos de motilida.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990602A (en) * 1986-12-17 1991-02-05 Taisho Pharmaceutical Co., Ltd. Erythromycin A derivatives
WO1997019096A2 (en) * 1995-11-21 1997-05-29 Abbott Laboratories Process for 6-o-alkylation of erythromycin derivatives

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS572298A (en) * 1980-06-04 1982-01-07 Taisho Pharmaceut Co Ltd Erythromycin derivative
JPS5782400A (en) 1980-11-12 1982-05-22 Taisho Pharmaceut Co Ltd Erythromycin derivative
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60214796A (ja) 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
US4670549A (en) * 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
DE3782994T2 (de) 1986-09-18 1993-04-08 Taisho Pharma Co Ltd Erythromycin-a-derivate und verfahren zu ihrer herstellung.
JPH0755958B2 (ja) * 1986-10-03 1995-06-14 大正製薬株式会社 エリスロマイシンａ誘導体の製造方法
JP2526951B2 (ja) * 1986-12-17 1996-08-21 大正製薬株式会社 エリスロマイシンａ誘導体およびその製造方法
JP2782793B2 (ja) * 1988-06-15 1998-08-06 大正製薬株式会社 エリスロマイシンａ誘導体およびその製造方法
ZA922776B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical compounds
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990602A (en) * 1986-12-17 1991-02-05 Taisho Pharmaceutical Co., Ltd. Erythromycin A derivatives
WO1997019096A2 (en) * 1995-11-21 1997-05-29 Abbott Laboratories Process for 6-o-alkylation of erythromycin derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
H.IWASAKI ET AL.: "Structure of 6-O-Methylerythromycin A (Clarithromycin).", ACTA CRYSTALLOGRAPHICA, vol. c49, no. 5, 15 May 1993 (1993-05-15), pages 1227 - 1230, XP002043675 *
K.H.KIM ET AL.: "Conformational Study of Erythromycin Analogues.", QSAR : QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS IN DRUG DESIGN, vol. 291, 1989, pages 325 - 328, XP002043674 *

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
WO1998031699A1 (en) * 1997-01-17 1998-07-23 Abbott Laboratories Crystal form 0 of clarithromycin
USRE39087E1 (en) 1998-08-21 2006-05-02 Apotex, Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
WO2000014099A1 (en) * 1998-09-09 2000-03-16 Hanmi Pharm. Co., Ltd. Method of preparing form ii crystals of clarithromycin
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
WO2000035934A1 (en) * 1998-12-11 2000-06-22 Biochemie S.A. Macrolide intermediates in the preparation of clarithromycin
US6599886B2 (en) 1998-12-11 2003-07-29 Biochemie S.A. Macrolide intermediates in the preparation of clarithromycin
KR20010008496A (ko) * 1999-07-01 2001-02-05 유충식 6-오-메틸 에리트로마이신의 제조방법
EP1097938A1 (en) * 1999-10-21 2001-05-09 Hanmi Pharm. Co., Ltd. Method for preparing form II crystals of clarithromycin
US6627743B1 (en) 1999-12-03 2003-09-30 Abbott Laboratories 6-O-methylerythromycin A crystal form III
EP1254146A4 (en) * 1999-12-16 2003-04-16 Teva Pharma PROCESSES FOR THE PREPARATION OF CLARITHROMYCIN POLYMORPHS AND A NEW POLYMORPH IV
US6599884B2 (en) 1999-12-16 2003-07-29 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs and novel polymorph IV
US6624292B2 (en) 2000-01-11 2003-09-23 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
EP1280535A4 (en) * 2000-01-11 2003-02-05 Teva Pharma PROCESSES FOR THE PREPARATION OF POLYMORPHIC FORMS OF CLARITHROMYCIN
US6987175B2 (en) 2000-01-11 2006-01-17 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
US7101858B2 (en) 2000-02-29 2006-09-05 Teva Pharmaceutical Industries, Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
US6617436B2 (en) 2000-02-29 2003-09-09 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
US6515116B2 (en) 2000-03-15 2003-02-04 Hanmi Pharm. Co., Method of preparing form II crystals of clarithromycin
KR100361397B1 (ko) * 2000-03-15 2002-11-23 한미약품공업 주식회사 에리스로마이신 에이 9-오-트로필옥심 유도체를 이용한클라리스로마이신의 제조방법
EP1134229A3 (en) * 2000-03-15 2002-02-27 Hanmi Pharm. Co., Ltd. Method of preparing clarithromycin of form II crystals
WO2001068662A1 (en) * 2000-03-15 2001-09-20 Hanmi Pharm. Co., Ltd. Method of preparing clarithromycin of form ii crystals
AU771825B2 (en) * 2000-03-15 2004-04-01 Hanmi Pharm. Co., Ltd. Method of preparing clarithromycin of form II crystals
RU2230748C2 (ru) * 2000-03-15 2004-06-20 Ханми Фарм. Ко., Лтд. Способ получения кларитромицина в виде кристаллов формы ii
KR100367981B1 (ko) * 2000-11-23 2003-01-14 한미약품공업 주식회사 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물
KR100408848B1 (ko) * 2001-03-12 2003-12-06 주식회사 씨트리 클래리스로마이신의 정제방법
WO2002094843A1 (en) * 2001-05-22 2002-11-28 Pfizer Products Inc. Crystal forms of azithromycin
EA007618B1 (ru) * 2001-05-22 2006-12-29 Пфайзер Продактс Инк. Кристаллический полуторогидрат азитромицина, содержащая его фармацевтическая композиция и способ лечения на его основе
US7309782B2 (en) 2001-05-22 2007-12-18 Pfizer Inc. Crystal forms of azithromycin
US7307156B2 (en) 2001-05-22 2007-12-11 Pfizer Inc. Crystal forms of azithromycin
EP1652851A1 (en) * 2001-05-22 2006-05-03 Pfizer Products Inc. New crystal form of Azithromycin
US7053192B2 (en) 2001-05-22 2006-05-30 Pfizer Inc. Crystal forms of azithromycin
EP1671979A1 (en) * 2001-05-22 2006-06-21 Pfizer Products Inc. New Cristal Form of Azithromycin
US7081525B2 (en) 2001-05-22 2006-07-25 Pfizer Inc. Crystal forms of azithromycin
US6977243B2 (en) 2001-05-22 2005-12-20 Pfizer Inc. Crystal forms of azithromycin
US6861413B2 (en) 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
US7105179B2 (en) 2001-05-22 2006-09-12 Pfizer Inc. Crystal forms of azithromycin
AU2002256846B2 (en) * 2001-05-22 2007-04-05 Pfizer Products Inc. Crystal Forms of Azithromycin
US7282486B2 (en) 2001-05-22 2007-10-16 Pfizer Inc Crystal forms of azithromycin
WO2004007518A1 (en) * 2002-07-15 2004-01-22 Korea United Pharm, Inc. Erythromycin a 9-o-pseudosaccharinyloxime derivatives and process for the preparation of clarithromycin using the same
EP1435359A1 (en) * 2002-12-31 2004-07-07 Alembic Limited A process for the purification of roxithromycin
DE102007016367A1 (de) 2007-04-03 2008-10-09 Grünenthal GmbH Polymorph von Clarithromycin (Form V)
WO2008119543A1 (de) * 2007-04-03 2008-10-09 Grünenthal GmbH Polymorph von clarithromycin (form v)
CN103087130A (zh) * 2013-02-06 2013-05-08 浙江国邦药业有限公司 一种克拉霉素晶型转换方法

Also Published As

Publication number Publication date
DE29724846U1 (de) 2004-12-16
CA2261732A1 (en) 1998-02-05
DE69730138D1 (de) 2004-09-30
JP2006137765A (ja) 2006-06-01
KR100524214B1 (ko) 2005-11-01
KR20000029591A (ko) 2000-05-25
JP2013151542A (ja) 2013-08-08
ES2173057T1 (es) 2002-10-16
DE97934319T1 (de) 2004-08-26
IL127833A0 (en) 1999-10-28
JP2009242411A (ja) 2009-10-22
ATE272646T1 (de) 2004-08-15
AU733646B2 (en) 2001-05-17
EP0915899A1 (en) 1999-05-19
CA2261732C (en) 2001-07-24
DE69730138T2 (de) 2005-03-03
DK0915899T3 (da) 2004-11-29
IL127833A (en) 2004-06-20
JP2002514171A (ja) 2002-05-14
PT915899E (pt) 2004-11-30
AU3740597A (en) 1998-02-20
ES2173057T3 (es) 2004-11-16
EP0915899B1 (en) 2004-08-04
JP4104660B2 (ja) 2008-06-18

Similar Documents

Publication Publication Date Title
US5844105A (en) Preparation of crystal form II of clarithromycin
EP0915899B1 (en) Preparation of crystal form ii of clarithromycin
US5858986A (en) Crystal form I of clarithromycin
EP1280535B1 (en) Processes for preparing clarithromycin polymorphs
RU2230748C2 (ru) Способ получения кларитромицина в виде кристаллов формы ii
AU783055B2 (en) Processes for preparing clarithromycin polymorphs and novel polymorph IV
CA2401571A1 (en) Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
AU2001225787A1 (en) Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
WO2001040242A2 (en) 6-o-methylerythromycin a crystal form iii
CA2386527C (en) Crystal form i of clarithromycin
CA2488397C (en) Crystal form ii of clarithromycin
CA2386534C (en) Crystal form ii of clarithromycin and uses thereof
AU777612B2 (en) Crystal form I of clarithromycin
US20050164958A1 (en) O-alkyl macrolide and azalide derivatives and regioselective process for their preparation
AU2005203314A1 (en) Processes for preparing clarithromycin polymorphs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN CZ IL JP KR MX NZ SG TR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997934319

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2261732

Country of ref document: CA

Ref country code: CA

Ref document number: 2261732

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1019997000654

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/001129

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1997934319

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997000654

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 160666

Country of ref document: IL

WWG Wipo information: grant in national office

Ref document number: 1997934319

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019997000654

Country of ref document: KR